New Campaign To Spur Clinical Trial Recruitment
17th May 18
The Australian Government has launched a national awareness campaign to get more Australians into ground-breaking clinical trials with the objective of offering better diagnosis, treatment and ultimately care.
Key Issues For The Dental Industry —
A new initiative, the Helping our Health campaign seeks to raise awareness of the role and value of clinical trials and to boost patient recruitment.
Clinical trials are an important part of making sure medicines and medical devices that can improve health are safe and effective for everyone. Currently, there are over 1000 clinical trials recruiting for candidate patients in Australia.
The Helping our Health campaign will feature a range of social and digital advertisements telling the success stories of Australian patients who have been through, and benefited from clinical trials, encouraging people to sign up for a clinical trial.
For information on the Helping Our Health campaign visit the Australian Clinical Trials website at:
The awareness campaign will be led by four-time AFL premiership player and Hawthorn Football Club Captain, Jarryd Roughead. Mr Roughhead will be the official ambassador for the campaign and signed up after gaining an understanding of the importance and benefits of clinical trials following his own health scare.
In 2016 Mr Roughead received news that a melanoma on his lip, detected and removed in 2015, had spread. A biopsy confirmed four small spots on Mr Roughead's lungs were cancerous. His treating doctor Professor Grant McArthur from the Peter MacCallum Centre, suggested that he consider a new immunotherapy treatment that was at the time being tested in clinical trials. The clinical trial tested the effect of a combination of two immunotherapy drugs, Opdivo (nivolumab) and Yervoy (Ipilimumab). Mr. Roughhead began treatment in June 2016 and by November 2016 was given the official all clear and declared cancer free. This is the power of clinical trials and we want more Australians to access them. They offer hope of better diagnosis, treatment and ultimately cure.
The Helping our Health initiative follows the announcement in the 2018 Australian Government Budget of a $248 million investment to support clinical trials for Australian patients with rare cancers and rare diseases, and unmet need clinical trials and registries program.
Member Engagement —
ADIA provides leadership, strategy, advocacy and support. Our members set our agenda, fund our activities and directly benefit from the results. With respect to the Association's work to support to support Australia's clinical trials framework team in the ADIA national office receive advice and guidance from members serving on the ADIA-PRPC Product Regulation Policy Committee.
Further Information —
To keep up to date with how ADIA is working with the Australian Government to reduce red-tape subscribe to the Twitter feed @AusDental or follow us on Facebook at www.facebook.com/dental.industry. Alternatively, you can contact the Association via email at firstname.lastname@example.org or by telephone on 1300 943 094.
Currency Of Information & Disclaimer —
This update was issued on 17 May 2018 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, images and where stated.
5th Jan 18
Ensuring that decisions taken by dental professionals on patient diagnostic and treatment options are independent of undue influence by product suppliers is what underpins the industry's new code of practice.
5th Mar 18
The TGA is proposing to levy for the first time an application fee for placing Class 1 medical devices on the Australian Register of Therapeutic Goods (ARTG), a proposal that will significantly add business compliance costs.